Gastrointestinal symptoms, including nausea, vomiting, and reflux, were the most common adverse events and were more frequent in semaglutide recipients
The term GLP-1s refers to medications that mimic or activate the hormone glucagonlike peptide1
For the reason, human subjects were provided lycopene for two months following LDL and MDA assessment
Their primary mechanisms of action include: Enhancing glucose-dependent insulin secretion from pancreatic beta cells Suppressing glucagon release , thereby reducing hepatic glucose production Slowing gastric emptying , which moderates post-meal glucose spikes Reducing appetite through central nervous system effects, particularly in hypothalamic regions Promoting satiety , leading to reduced caloric intake These medications have demonstrated significant benefits in glycaemic control, weight reduction, and cardiovascular risk reduction in clinical trials
The effects of semaglutide on the birth control pill are still unclear
The Future of GLP-1 Therapy The future of GLP-1 therapy is promising